STAAR Surgical reports Q3 net sales up 10% to $88.6M; revises 2024 regional growth assumptions

STAAR SURGICAL CO

2024-Q3 EPS reported $0.28 revenue$264,951,000

Net income of $10.0M ($0.20 EPS) vs $4.8M ($0.10 EPS) a year ago; adjusted EBITDA $16.2M.
ICL sales $89.1M, up 10%; gross margin 77.3% vs 79.2% on lower production absorption.
FY 2024 net sales outlook maintained at $340-345M; adjusted EBITDA ~$42M.
Americas EVO ICL growth revised to 17% (was 15%); U.S. to 20% (was 25%); EMEA to 10% (was 6%).
APAC growth cut to 5% (was 7%); China growth slashed to ~2% (was 10%); other APAC now 10-20% (was flat).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.